Cargando…
Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★
In this historical cohort study, 236 patients with primary rheumatoid arthritis were treated with the tumor necrosis factor inhibitors, etanercept or infliximab (n = 80), or by conventional methods (n = 156). Results revealed that 11 patients developed varying types of peripheral neuropathy at 1–2 y...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342715/ https://www.ncbi.nlm.nih.gov/pubmed/25737715 http://dx.doi.org/10.3969/j.issn.1673-5374.2012.11.011 |
_version_ | 1782359309174177792 |
---|---|
author | Wang, Naizhi Guo, Yingying Yang, Lili Fu, Wenyi Xu, Yanbing Hou, Linxin Zhao, Shuai Zhang, Ning |
author_facet | Wang, Naizhi Guo, Yingying Yang, Lili Fu, Wenyi Xu, Yanbing Hou, Linxin Zhao, Shuai Zhang, Ning |
author_sort | Wang, Naizhi |
collection | PubMed |
description | In this historical cohort study, 236 patients with primary rheumatoid arthritis were treated with the tumor necrosis factor inhibitors, etanercept or infliximab (n = 80), or by conventional methods (n = 156). Results revealed that 11 patients developed varying types of peripheral neuropathy at 1–2 years post-treatment (mean 16 months). The incidence of peripheral neuropathy in the tumor necrosis factor inhibitors treatment group was 8.8% (7/80), which was significantly higher than the conventional treatment group (2.6%; 4/156). The relative risk of developing peripheral neuropathy in the tumor necrosis factor inhibitors treatment group was 3.41 (95% confidence interval: 1.03–11.31). Comparison of the tumor necrosis factor inhibitors revealed that etanercept and infliximab had no significant difference in terms of inducing peripheral neuropathy. Experimental findings indicate that tumor necrosis factor inhibitors may increase the risk of peripheral neuropathy. |
format | Online Article Text |
id | pubmed-4342715 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-43427152015-03-03 Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★ Wang, Naizhi Guo, Yingying Yang, Lili Fu, Wenyi Xu, Yanbing Hou, Linxin Zhao, Shuai Zhang, Ning Neural Regen Res Clinical Practice In this historical cohort study, 236 patients with primary rheumatoid arthritis were treated with the tumor necrosis factor inhibitors, etanercept or infliximab (n = 80), or by conventional methods (n = 156). Results revealed that 11 patients developed varying types of peripheral neuropathy at 1–2 years post-treatment (mean 16 months). The incidence of peripheral neuropathy in the tumor necrosis factor inhibitors treatment group was 8.8% (7/80), which was significantly higher than the conventional treatment group (2.6%; 4/156). The relative risk of developing peripheral neuropathy in the tumor necrosis factor inhibitors treatment group was 3.41 (95% confidence interval: 1.03–11.31). Comparison of the tumor necrosis factor inhibitors revealed that etanercept and infliximab had no significant difference in terms of inducing peripheral neuropathy. Experimental findings indicate that tumor necrosis factor inhibitors may increase the risk of peripheral neuropathy. Medknow Publications & Media Pvt Ltd 2012-04-15 /pmc/articles/PMC4342715/ /pubmed/25737715 http://dx.doi.org/10.3969/j.issn.1673-5374.2012.11.011 Text en Copyright: © Neural Regeneration Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Practice Wang, Naizhi Guo, Yingying Yang, Lili Fu, Wenyi Xu, Yanbing Hou, Linxin Zhao, Shuai Zhang, Ning Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★ |
title | Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★ |
title_full | Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★ |
title_fullStr | Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★ |
title_full_unstemmed | Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★ |
title_short | Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★ |
title_sort | effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: a cohort study★ |
topic | Clinical Practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342715/ https://www.ncbi.nlm.nih.gov/pubmed/25737715 http://dx.doi.org/10.3969/j.issn.1673-5374.2012.11.011 |
work_keys_str_mv | AT wangnaizhi effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy AT guoyingying effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy AT yanglili effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy AT fuwenyi effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy AT xuyanbing effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy AT houlinxin effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy AT zhaoshuai effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy AT zhangning effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy |